Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edasalonexent Extension in Pediatric Duchenne Muscular Dystrophy
NCT03917719Phase 3Terminated
- Sponsor
- Astria Therapeutics
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of edasalonexent in Duchenne muscular dystrophy (DMD), sponsored by Astria Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 104 weeks. Started Mar 2019; status: terminated.
02
Drugs
edasalonexent
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03917719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917719.